CoChat

The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer

Open access
Pan, Mei-Ren, Hsu, Ming-Chuan, Luo, Chi-Wen, Chen, Li-Tzong, Shan, Yan-Shen, Hung, Wen-Chun · 2016 · Oncotarget
Cited by 56

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

// Mei-Ren Pan 1, 2 , Ming-Chuan Hsu 3 , Chi-Wen Luo 4 , Li-Tzong Chen 3, 5 , Yan-Shen Shan 6, 7 , Wen-Chun Hung 3, 8 1 Graduate Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan 2 Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan 3 National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan 4 Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan 5 Division of Hematology/Oncology, Department of Internal Medicine, National Cheng Kung University Hospital, Tainan 704, Taiwan 6 Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan 7 Department of Surgery, National Cheng Kung University Hospital, Tainan 704, Taiwan 8 Institute of Basic Medical Sciences, National Cheng Kung University, Tainan 704, Taiwan Correspondence to: Wen-Chun Hung, email: hung1228@nhri.org.tw Keywords: lysine demethylase, drug resistance, interleukin-8, pancreatic stellate cell Received: February 25, 2016 Accepted: July 27, 2016 Published: August 12, 2016 ABSTRACT Gemcitabine (GEM) resistance is a critical issue for pancreatic cancer treatment. The involvement of epigenetic modification in GEM resistance is still unclear. We established a GEM-resistant subline PANC-1-R from the parental PANC-1 pancreatic cancer cells and found the elevation of various chromatin-modifying enzymes including G9a in GEM-resistant cells. Ectopic expression of G9a in PANC-1 cells increased GEM resistance while inactivation of G9a in PANC-1-R cells reduced it. Challenge of PANC-1 cells with GEM increased the expression of stemness markers including CD133, nestin and Lgr5 and promoted sphere forming activity suggesting chemotherapy enriched cancer cells with stem-like properties. Inhibition of G9a in PANC-1-R cells reduced stemness and invasiveness and sensitized the cells to GEM. We revealed interleukin-8 (IL-8) is a downstream effector of G9a to increase GEM resistance. G9a-overexpressing PANC-1-R cells exhibited autocrine IL-8/CXCR1/2 stimulation to increase GEM resistance which could be decreased by anti-IL-8 antibody and G9a inhibitor. IL-8 released by cancer cells also activated pancreatic stellate cell (PSC) to increase GEM resistance. In orthotopic animal model, GEM could not suppress tumor growth of PANC-1-R cells and eventually promoted tumor metastasis. Combination with G9a inhibitor and GEM reduced tumor growth, metastasis, IL-8 expression and PSC activation in animals. Finally, we showed that overexpression of G9a correlated with poor survival and early recurrence in pancreatic cancer patients. Collectively, our results suggest G9a is a therapeutic target to override GEM resistance in the treatment of pancreatic cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.11256

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 56

Metadata

Authors
Pan, M.-R., Hsu, M.-C., Luo, C.-W., Chen, L.-T., Shan, Y.-S., & Hung, W.-C.
Venue
Oncotarget
Published
2016-08-12
Volume
7
Issue
38
Pages
61136-61151
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2518599328
Cited by
56
References
2
FWCI
3.71
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. https://app.cochat.ai/papers/10.18632/oncotarget.11256
The paper
Pan, M.-R., Hsu, M.-C., Luo, C.-W., Chen, L.-T., Shan, Y.-S., & Hung, W.-C. (2016). The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer. Oncotarget. https://doi.org/10.18632/oncotarget.11256

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.